Inovio Pharma Cmn (NASDAQ:INO) shares traded -2.33% down during most recent session to reach at the closing price of $6.29. The stock exchanged hands 1.21 Million shares versus average trading capacity of 1.58 Million shares, yielding a market cap of $550.56 Million. Wall Street analysts covering the stock are projecting that the stock will reach $11.83 within the next 52-weeks. The mean target projections are based on 6 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Inovio Pharma Cmn (NASDAQ:INO) high price target of $14 and with a conservative view have low price target of $10.

PiperJaffray “Upgrades” Inovio Pharma Cmn (NASDAQ:INO) in a research note issued to investors on 6/08/17 to Overweight with price target of $0.

Additionally on 3/16/17 PiperJaffray “Downgrades” Inovio Pharma Cmn (NASDAQ:INO) to Neutral setting price target at $9 and on 11/07/16 Aegis Capital “Initiates Coverage On” the stock to Buy. Furthermore on 10/04/16 Brean Capital “Assumes” the stock to Buy at $18.

On the other hand the company has Relative Strength Index (RSI 14) of 51.73 along with Average True Range (ATR 14) of 0.22, Consequently Inovio Pharma Cmn (NASDAQ:INO)’s weekly and monthly volatility is 3.85%, 3.16% respectively. The company’s beta value is at 2.96.

In terms of Buy, Sell or Hold recommendations, Inovio Pharma Cmn (NASDAQ:INO) has analysts’ mean recommendation of 1.7. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Inovio Pharma Cmn (NASDAQ:INO)’s minimum EPS for the current quarter is at $-0.29 and can go high up to $-0.13. The consensus mean EPS for the current quarter is at $-0.24 derived from a total of 6 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.28 earnings per share for the same quarter during last year.

Previously Inovio Pharma Cmn (NASDAQ:INO) reported $-0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.19 by $0.06. The company posted an earnings surprise of 31.6%.

Inovio Pharma Cmn (NASDAQ:INO)’s revenue estimates for the current quarter are $10.27 Million according to 5 number of analysts, for the current quarter the company has high revenue estimates of $20.87 Million in contradiction of low revenue estimates of $5.5 Million. For the current year the company’s revenue estimates are $51.27 Million compared to low analyst estimates of $41.79 Million and high estimates of $72.61 Million according to 5 number of analysts.

Currently Inovio Pharma Cmn (NASDAQ:INO)’s shares owned by insiders are 3.6%, whereas shares owned by institutional owners are 25.2%. However the six-month change in the insider ownership was recorded -0.25%, as well as three-month change in the institutional ownership was recorded -0.18%.

Inovio Pharma Cmn (NASDAQ:INO) 52-week high price stands at $9.86 and low price stands at $5.28, its price distance from 52-week high is -36.21% while its distance from 52-week low price is 19.13%. The stock hit its 52-week high on 05/24/17, and 52-week low on 08/18/17.

Inovio Pharma Cmn (NASDAQ:INO)’s trailing twelve month revenues are $51.8 Million, whereas its price to sales ratio for the same period is 10.63. Its book value per share for the most recent quarter is $1.64 while its price to book ratio for the same period is 3.84, as for as the company’s cash per share for the most recent quarter is $1.05, however its price to cash per share ratio for the same period is 5.98. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.